Company news

MiNK Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 21, 2024

MiNK Reports First Quarter 2024 Results

May 13, 2024

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

May 12, 2024

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

April 29, 2024

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

April 7, 2024

MiNK Reports Fourth Quarter and Year-End 2023 Results

March 20, 2024

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

March 6, 2024

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

March 5, 2024

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

February 13, 2024

MiNK Therapeutics Reports Third Quarter 2023 Results

November 8, 2023

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

October 29, 2023

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

September 26, 2023

MiNK Therapeutics Reports Second Quarter 2023 Results

August 9, 2023

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

July 27, 2023

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

May 21, 2023

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

May 10, 2023

MiNK Therapeutics to Report First Quarter 2023 Corporate Update and Financial Results

April 26, 2023

MiNK Therapeutics Announces Clinical Data of Allogeneic iNKT Cells (agenT-797) in Solid Tumor Cancers at the AACR Annual Meeting

April 17, 2023

MiNK Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

March 20, 2023

MiNK Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results

March 6, 2023

MiNK Presents Clinical Data at SITC 2022 Showcasing iNKT Cell Therapy Pipeline

November 9, 2022

MiNK Therapeutics Reports Corporate Update and Third Quarter 2022 Financial Results

November 2, 2022

MiNK Therapeutics to Report Third Quarter 2022 Financial Results and Business Update

October 19, 2022

MiNK Therapeutics to Host R&D Event November 10, 2022

October 4, 2022

MiNK Selected for Five Presentations at Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

October 4, 2022

MiNK Therapeutics Reports Corporate Update and Second Quarter 2022 Financial Results

August 8, 2022

MiNK Therapeutics to Report Second Quarter 2022 Financial Results and Business Update

July 26, 2022

MiNK Therapeutics Corporate Update and First Quarter 2022 Financial Report

May 9, 2022

MiNK Therapeutics to Report First Quarter 2022 Financial Results and Business Update

April 26, 2022

MiNK Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results

March 17, 2022

MiNK Therapeutics Announces Patients Dosed with AgenT-797 iNKT Cell Therapy in Solid Tumor Cancers

March 2, 2022

MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with AgenT-797

November 11, 2021

MiNK Therapeutics Presents New Preclinical and Clinical Data on iNKT Cell Therapy Programs at SITC 2021

November 8, 2021

MiNK Therapeutics Announces Closing of Initial Public Offering

October 18, 2021

MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering

October 13, 2021

← Newer news releases

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks